INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative factors: XPro's Phase II trial failure, financial losses, and reliance on future funding. Despite potential in CORDStrom's expansion and sufficient cash reserves, regulatory risks and manufacturing challenges persist. The Q&A section did not alleviate concerns, and recent stock offerings could dilute value. These outweigh the positives, suggesting a negative stock price movement.
Key Financial Performance
Net loss attributable to common stockholders Approximately $45.9 million for the year ended December 31, 2025, compared to approximately $42.1 million for 2024. The increase is due to various operational factors.
Research and development expenses Approximately $20.7 million for the year ended December 31, 2025, compared with approximately $33.2 million for 2024. The decrease is attributed to lower expenses incurred in connection with the Alzheimer's trial in 2025.
General and administrative (G&A) expenses Approximately $10.3 million for the year ended December 31, 2025, compared with approximately $9.5 million for 2024. The increase is due to higher operational costs.
Impairment of intangible asset A full impairment of $16.5 million was recorded in 2025 following the release of the Phase II results of the Alzheimer's trial, which did not meet the clinical endpoint.
Cash and cash equivalents Approximately $24.8 million as of December 31, 2025. This reflects the company's financial position at the end of the fiscal year.
Proceeds from stock offerings The company sold 3 million shares of common stock for net proceeds of approximately $17.4 million in a registered direct offering. Additionally, approximately 1.3 million shares of common stock were sold for net proceeds of approximately $10.1 million under at-the-market offerings.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CORDStrom: Progressed towards registration for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). Demonstrated clinical meaningful wound healing, reduced itch, and improved quality of life with a favorable safety profile. Regulatory submissions in the U.K. and U.S. are planned, with the U.K. submission expected by summer 2026. The platform has potential applications in other inflammatory and degenerative conditions, as well as genetically modified applications in oncology and rare diseases.
XPro: Completed the MINDFuL Alzheimer's trial and aligned with the FDA on the development path for Phase III. The trial showed encouraging results in treating Alzheimer's pathology and inflammation. The Phase III program is designed as an adaptive trial with a decision point at 9 months and a registrational stage at 18 months. The program is built on a solid foundation with ongoing preparations for initiation.
INKmune: Completed Phase II trial in metastatic castration-resistant prostate cancer ahead of schedule and under budget. The study met its primary endpoint and two of its three secondary endpoints.
Financial Performance: Net loss for 2025 was $45.9 million compared to $42.1 million in 2024. Research and development expenses decreased to $20.7 million in 2025 from $33.2 million in 2024 due to lower Alzheimer's trial expenses. General and administrative expenses increased slightly to $10.3 million in 2025 from $9.5 million in 2024. The company raised $27.5 million through stock offerings in 2025 and had $24.8 million in cash and equivalents at year-end, sufficient to fund operations through Q1 2027.
Regulatory and Commercial Strategy: Focused on advancing CORDStrom towards regulatory approval in the U.K., EU, and U.S. by the end of 2026. Preparing for Phase III development of XPro with FDA alignment and pursuing partnerships and funding for late-stage development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Milestones: Aggressive timelines for regulatory submissions in the U.K., EU, and U.S. for CORDStrom by the end of 2026 may pose risks of delays or non-compliance with regulatory requirements.
Manufacturing and Scalability: Ensuring batch-to-batch manufacturing consistency and scalability for CORDStrom, especially given its reliance on pooled donor cell banks, could face challenges.
Financial Sustainability: The company reported a net loss of $45.9 million in 2025 and relies on cash reserves projected to last until Q1 2027, creating financial pressure to secure additional funding or partnerships.
Alzheimer's Program (XPro): The Phase II Alzheimer's trial did not meet its clinical endpoint, raising concerns about the viability of the program and the ability to secure partnerships or funding for Phase III.
Market and Commercialization Risks: Delays in regulatory approvals or challenges in demonstrating commercial viability for CORDStrom and XPro could impact revenue generation and market positioning.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
CORDStrom Regulatory Submissions: The company plans to file the Marketing Authorization Application (MAA) for CORDStrom in the U.K. by mid-summer 2026, followed by submissions to the EMA and FDA by the end of 2026. Approvals or feedback are expected in 2027.
CORDStrom Commercialization Timeline: If regulatory approvals are obtained, the company aims to supply CORDStrom to RDEB patients by 2027.
CORDStrom Platform Expansion: Beyond RDEB, the company is exploring broader applications of CORDStrom in inflammatory and degenerative conditions, as well as genetically modified applications in oncology and rare diseases.
XPro Phase III Development: The company is preparing for a Phase III trial for XPro in Alzheimer's disease, designed as an adaptive trial with a decision point at 9 months and a registrational stage at 18 months. The trial design has received alignment from the FDA.
XPro Funding and Partnerships: The company is actively pursuing partnerships and funding to support the late-stage development of XPro.
Financial Outlook: The company has sufficient cash to fund operations through Q1 2027, based on its current operating plan.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there any anticipated differences between an MAA and an FDA submission? Have you had interactions with the FDA, and what might be their requirements compared to European or U.K. agencies?
A:The FDA requires U.K. donor materials to be screened for globally agreed infectious disease markers in U.S. labs. A new master seedstock is being created to meet this requirement. The rest of the FDA's requirements are identical to those from the MHRA. The company plans to submit a pre-MAA package to the MHRA and then use the feedback for a Type B meeting with the FDA in preparation for the BLA.
Q:Would you have to have the samples tested in U.S. labs before submission, or can this be done during the evaluation?
A:The FDA requires confirmation that only drug products from U.S.-tested donors will be supplied to the U.S. The company is already making the master cell batch from U.S.-tested donors and will have these products ready before submitting the BLA.
Q:Have you had any interactions with potential former partners at ABPD regarding the XPro program?
A:The company has ongoing discussions with groups, including midsized biotech companies and large pharma. They are seeking a partner to help with business development. The Phase IIb portion of the program is seen as a relatively small investment with a clear path to registration if the results align with expectations. The program is considered attractive due to its logical correlation between cognitive aspects and functional scales.
Q:Review of Unclear Management Responses
A:No questions were avoided or lacked clarity in the responses provided by management.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alzheimer pathology
Alzheimer trial
CEO
CJ update
FDA
INmune Bio
Phase II
Phase III
RDEB patient
UK
bank donor
body inflammation
cell bank
cell product
cell skin
cytokine
development
disease indication
donor cell
endpoint
family
itch
marketing authorization
mechanism action
partnership
program
stage
update XPro
wound
INMB Transcript
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call reveals several negative factors: XPro's Phase II trial failure, financial losses, and reliance on future funding. Despite potential in CORDStrom's expansion and sufficient cash reserves, regulatory risks and manufacturing challenges persist. The Q&A section did not alleviate concerns, and recent stock offerings could dilute value. These outweigh the positives, suggesting a negative stock price movement.
Coveo Solutions Inc. (CVO:CA) Q2 2026 Earnings Call Transcript
Unknown10-30
The earnings call presents a mixed sentiment. Positive aspects include strong generative AI revenue growth and successful commerce bookings. However, the renegotiated Salesforce contract and negative cash flow are concerns. The Q&A reveals some uncertainties, such as delayed deals and the impact of the Salesforce contract on guidance. Overall, these factors balance each other, leading to a neutral sentiment. Without market cap data, the stock's reaction is uncertain, but the mixed signals suggest limited short-term movement.
INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
Unknown10-30
The earnings call reveals several negative factors: a delay in the XPro FDA meeting, limited efficacy in the INKmune trial, and cautious partnership progress. While financial losses decreased and cash runway extends to Q4 2026, the need for additional financing looms. The Q&A session highlights uncertainties and management's reluctance to provide detailed guidance. These elements, combined with the lack of a new partnership announcement or strong guidance, suggest a negative stock price movement in the short term.
INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. Financial performance shows a significant net loss due to impairment, but cost-saving measures are in place. Product development is promising with positive feedback on XPro, but faces delays and dependence on partnerships. Market strategy is cautious, focusing on rare diseases. Cash reserves are adequate for the near term. Q&A highlights potential partnerships post-FDA meeting, but uncertainties remain. Overall, the sentiment balances out, leading to a neutral rating, with no strong catalysts for a significant stock price movement in the short term.
INMB Slides
INMB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
